565
Views
18
CrossRef citations to date
0
Altmetric
Infectious Diseases

Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 405-409 | Received 15 Mar 2018, Accepted 14 Jul 2018, Published online: 23 Oct 2018

References

  • Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144:4–11.
  • Ahmed I, Agarwal S, Ilchyshyn A, et al. Liquid nitrogen cryotherapy of common warts: cryospray vs. cotton wool bud. Br J Dermatol. 2001;144:1006–1009.
  • Bacelieri R, Johnson SM. Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 2005;72:647–652.
  • Theng TSC, Goh BK, Chong WS, et al. Viral warts in children seen at a tertiary referral centre. Ann Acad Med Singap. 2004;33:53–56.
  • Clifton MM, Johnson SM, Roberson PK, et al. Immunotherapy for recalcitrant warts in children using intralesional mumps or candida antigens. Pediatr Dermatol. 2003;20:268–271.
  • Horn TD, Johnson SM, Helm RM, et al. Intralesional immunotherapy of warts with mumps, candida, and trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005;141:589–594.
  • Nofal A, Nofal E. Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010;24:1166–1170.
  • Venugopal SS, Murrell DF. Recalcitrant cutaneous warts treated with recombinant quadrivalent papilloma virus vaccine (type 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol. 2010;146:475–477.
  • Landis MN, Lookingbill DP, Sluzevich JC. Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine. J Am Acad Dermatol. 2012;67:73–74.
  • Daniel BS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivanlent human papillomavirus vaccine. JAMA Dermatol. 2013;149:370–372.
  • Crawford NW, Clothier HJ, Elia S, et al. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. Med J Aust. 2011;194:16–18.
  • Androphy EJ, Kirnbauer R. Human papilloma virus infections. In: Wolff K, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraHill; 2012. Chapter 196. p. 2421–2433.
  • Kuflik EG. Specific indications for cryosurgery of the nail unit. Myxoid cysts and periungual verrucae. J Dermatol Surg Oncol. 1992;18:702–706.
  • Ebrahimi S, Dabiri N, Jamshidnejad E, et al. Efficacy of 10% silver nitrate solution in the treatment of common warts: a placebo-controlled, randomized, clinical trial. Int J Dermatol. 2007;46:215–217.,
  • Street ML, Roenigk RK. Recalcitrant periungual verrucae: the role of carbon dioxide laser vaporization. J Am Acad Dermatol. 1990;23:115–120.
  • Tan OT, Hurwitz RM, Stafford TJ. Pulsed dye laser treatment of recalcitrant verrucae: a preliminary report. Lasers Surg Med. 1993;13:127–137.
  • Langdon RE. Erbium:YAG laser enables complete ablation of periungual verrucae without the need for injected anesthetics. Dermatol Surg. 1998;24:157–158.
  • Micali G, Dall'Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat. 2003;14:233–236.
  • Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol. 2001;145:385–405.
  • Moghaddas N. Periungual verrucae diagnosis and treatment. Clin Podiatr Med Surg. 2004;21:651–661.
  • Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931–4939.
  • Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24:5571–5583.
  • Gee J, Weinbaum C, Sukumaran L, et al. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12:1406–1417.
  • Simonart T, de Maertelaer V. Systemic treatments for cutaneous warts: a systematic review. J Dermatolog Treat. 2012;23:72–77.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.